Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials -- Ignore unavailable to you. Want to Upgrade?

To: GPSite who wrote (14)	6/3/1999 6:09:00 PM
From: Tim Davies	Read Replies (1) \| Respond to of 250

does this stock trade someplace or is it a pink sheet .. ? tim

To: GPSite who wrote (14)	6/3/1999 6:36:00 PM
From: glen	Respond to of 250

Hello GPSite- It's nice to see that you signed up to SI especially for VaxGen, and even took your "nom de plume" based on their vaccine's biochemistry. Prudential may begin taking indications around June 14, 1999 for IPO shares. IPO tentatively scheduled for July 14, 1999.

To: GPSite who wrote (14)	6/3/1999 8:23:00 PM
From: glen	Read Replies (1) \| Respond to of 250

GP-YOU SAID IN POST #14, "The FDA wants to play ball. They set the efficacy level for approval at 30% -- a level that should be a slam-dunk for VaxGen's AIDSVAX. Why did they do that? Because the FDA wants to make it happen" There are some real answers as to why the FDA would give approval with as little as a 30% efficacy level. First, there is at this time no known cure for AIDS. Although great strides have been made in prolonging the life expectancy of those infected, all will eventually succomb. The cost to society in lost lives and, in dollars spent for research and providing health care, is absolutely staggering...just enormous. If only 3 out of every 10 people vaccinated became immune ti the HIV virus, then the benefits and savings would be in the hundresd of millions of dollars, if not billions. It is much less expensive for a governments/society to help underwrite the cost of a vaccination program than it is to have to provide years of medical care to AIDS victims. So, if VaxGen wins FDA approval, the upside potential is dazzling with an instant worldwide market that would easily take VaxGen's share price into triple digits. Where would you venture to guess this re-opens in the secondary market?